HonCode

Go Back   HER2 Support Group Forums > General Cancer News
Reload this Page Fulvestrant 500 mg reduces risk of disease progression in women with metastatic breas
Register Gallery FAQ Members List Calendar Today's Posts

General Cancer News Latest Breast Cancer News from Moreover Technologies

Reply
 
Thread Tools Display Modes
Old 12-10-2009, 10:41 PM   #1
News
Senior Member
 
News's Avatar
 
Join Date: Oct 2007
Posts: 18,983
Fulvestrant 500 mg reduces risk of disease progression in women with metastatic breas
AstraZeneca (NYSE: AZN) today announced that data from a Phase III study of postmenopausal women with hormone receptor-positive advanced breast cancer presented at the San Antonio Breast Cancer Symposium (Abstract 25) showed treatment with fulvestrant (FASLODEX) 500 mg reduced the risk of disease progression (assessed as time to progression (TTP)) by 20%

More...
News is offline   Reply With Quote
Reply

« Previous Thread | Next Thread »

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump


All times are GMT -7. The time now is 05:43 AM.
Contact Us - HER2 Support Group - Archive - Privacy Statement - Top

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter